Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from the Bristol-Myers Squibb and Pfizer Alliance.

Medical Crossfire®: Recognizing and Treating VTE in Patients With Cancer—Bridging Guideline-Based Recommendations With Real-World Evidence

Release Date: January 31, 2020
Expiration Date: January 31, 2021
Media: Internet - based

Activity Overview

As cancer incidence rates remain high, so does the risk of disease- or treatment-related complications, such as venous thromboembolism (VTE), leading to devastating functional losses and even death. In fact, VTE, comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), occurs 4- to 7-fold higher in patients with cancer compared with the general population. Because several different types of cancer are associated with a higher risk of clot formation, management of VTE requires a multidisciplinary approach to treatment and prophylaxis. It is imperative for oncologists and hematologists to have knowledge of VTE risk factors and stratification, management strategies using low-molecular weight heparins or direct oral anticoagulants, guideline-based recommendations for care, and methods for reducing recurrence following initial treatment.

This Medical Crossfire®: Recognizing and Treating VTE in Patients With Cancer—Bridging Guideline-Based Recommendations With Real-World Evidence online CME activity delivers opinions, insights, and philosophies from 3 experts in oncology and hematology who are well versed in the treatment of cancers that are associated with a high risk of VTE. A didactic overview of incidence, risk assessment, and guideline updates is followed by case presentations to assist in the application of key strategies into defined patient care scenarios. Case-based educational programs help clinicians not just understand the evolving data, but also incorporate new information into clinical practice in order to individualize VTE treatment and prevention for their patients with cancer.

Benefits of Participating

  • Appreciate the impact that cancer-related VTE has on patients’ lives
  • Improve your knowledge on how to identify patients who might be at high-risk of developing cancer-related VTE
  • Gain awareness of best practices for managing and treating patients with cancer-related VTE
  • Learn how the experts handle challenging, real-world clinical cases

Acknowledgement of Commercial Support

This activity is supported by an educational grant from the Bristol-Myers Squibb and Pfizer Alliance.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Videos” will be available for your reference.
  • In order to receive a CME Certificate, you must complete the activity.
  • Complete the Posttest and the Evaluation, and then click on “Request for Credit.” You may immediately download a CME Certificate upon completion of these steps.

Target Audience

This educational activity is intended for hematologists/oncologists, hematologists, and medical oncologists who treat patients with cancer-related venous thromboembolism (VTE). Fellow, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of cancer-related VTE are invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Recognize the prevalence, morbidity, and mortality rates as well as risk factors associated with development of VTE in patients with cancer.
  • Apply recent evidence-based guideline recommendations for the prevention and treatment of cancer-associated VTE into clinical practice.
  • Identify strategies for the prevention and treatment of VTE in patients with cancer, including the reduction of risk of recurrence following initial treatment.
  • Implement individualized anticoagulation regimens for prevention and treatment of VTE in patients with cancer that are based on the unique needs and characteristics of each patient.

Faculty, Staff, and Planners’ Disclosures


Sagar Lonial
Sagar Lonial, MD, FACP
Anne and Bernard Gray Family Professor and Department Chair
Department of Hematology and Medical Oncology
Emory University School of Medicine
Chief Medical Officer
Winship Cancer Institute
Emory University
Atlanta, GA

Disclosures: Grant Research Support: Celgene, Janssen, Takeda; Consultant: Celgene, Novartis, Bristol-Myers Squibb, Takeda, Janssen, GlaxoSmithKline, Amgen, AbbVie.

Kenneth A. Bauer
Kenneth A. Bauer, MD
Professor of Medicine and Hematologist
Harvard Medical School
Division of Hemostasis and Thrombosis
Beth Israel Deaconess Medical Center
Boston, MA

Disclosures: Consultant: Janssen.

Simon Mantha
Simon Mantha, MD, MPH
Associate Attending Physician and Hematologist
Hematology Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Other: Daboia Consulting LLC.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By